Tsukuba, Japan

Katsuhisa Kojiri

This inventor holds 17 USPTO granted patents, plus 2 CIPO patents. Top assignee: Banyu Pharmaceutical Co. Ltd. Active years: 1994-2004.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Katsuhisa Kojiri. Retrieved from https://idiyas.com/inventor/katsuhisa-kojiri

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 88.2


Average Co-Inventor Count = 5.0

ph-index = 6

Forward Citations = 86(Granted Patents)


Location History:

  • Isukuba, JP (1999)
  • Tsukuba, JP (1994 - 2001)
  • Tokyo, JP (1995 - 2004)

Company Filing History:


Years Active: 1994-2004

Loading Chart...
Loading Chart...
17 patents (USPTO):Explore Patents

Title: Innovations of Katsuhisa Kojiri

Introduction

Katsuhisa Kojiri is a prominent inventor based in Tsukuba, Japan. He has made significant contributions to the field of pharmaceuticals, holding a total of 17 patents. His work focuses on developing novel compounds with therapeutic applications.

Latest Patents

Among his latest patents are the indolopyrrolocarbazole derivatives and antitumor agents, as well as sesterterpene derivatives exhibiting antifungal activities. Additionally, he has developed a compound represented by the formula [I], showcasing his innovative approach to drug discovery.

Career Highlights

Katsuhisa Kojiri is associated with Banyu Pharmaceutical Co. Ltd., where he has been instrumental in advancing research and development efforts. His expertise in medicinal chemistry has led to breakthroughs in the creation of effective therapeutic agents.

Collaborations

He has collaborated with notable colleagues, including Hiroyuki Suda and Hisao Kondo, to further enhance the impact of his research. Their combined efforts have contributed to the success of various projects within the pharmaceutical industry.

Conclusion

Katsuhisa Kojiri's work exemplifies the spirit of innovation in the pharmaceutical field. His contributions through patents and collaborations continue to pave the way for new therapeutic solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…